Financing, expansion, and optimism across global biotech and pharma

Biotech and pharma are seeing a marked rebound, with sizable financings, strategic investments, and new infrastructure signaling renewed growth. Startups like Cognito Therapeutics, Nexcure, Ten63 Therapeutics, and Zura Bio are raising significant capital, while Candid Therapeutics pursues a reverse merger to go public and Asia inks multiple first-in-class drug development deals. Roche’s $481 million commitment to South Korea and a new $30 million biotech training center in Ohio highlight global capacity-building. Investor commentary and industry outlooks on majors like Eli Lilly, J&J, Sanofi, and Bayer underscore rising confidence in the next wave of medical innovation.